{"created":"2023-07-27T06:28:30.727139+00:00","id":13102,"links":{},"metadata":{"_buckets":{"deposit":"a45835f4-e47e-4cad-bdf9-23af2401246d"},"_deposit":{"created_by":3,"id":"13102","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"13102"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00013102","sets":["1132:1133:1134"]},"author_link":["20750","20756","20751","20753","20754","20752","20755"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2003-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"108","bibliographicPageStart":"105","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"Journal of Nuclear Medicine"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"This study used PET to measure the time course of the brain concentration of 18F-labeled N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, after oral administration to conscious rhesus monkeys. Methods: Three young-adult male rhesus monkeys were tested. FK960 (0.1 mg/kg) containing about 370 MBq of 18F-FK960 was administered orally to each monkey. Dynamic PET images were acquired for 4 h from 5 min after the administration. Arterial blood samples were withdrawn during PET scanning and were analyzed by an automatic well γ-counter and thin-layer chromatography to determine the time course of authentic 18F-FK960 activity concentration in plasma. FK960 concentrations in brain and plasma were calculated in units of mol/L using the specific activity of FK960 preparations. Results: 18F-FK960 penetrated the blood-brain barrier and underwent perfusion-dependent distribution in the entire brain. Maximal concentrations in the brain and plasma were 1.11 ± 0.30 x 10-7 mol/L (at 3.0 ± 0.6 h after administration) and 4.04 ± 1.29 x 10-7 mol/L (at 2.0 ± 1.1 h after administration), respectively. Conclusion: We succeeded in measuring the FK960 concentration in the brains of conscious monkeys and in plasma after oral administration at a dose of 0.1 mg/kg. The results suggested that this method can measure the FK960 concentration in the human brain, and a potential use of the PET technique in drug development was demonstrated.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学大学院医学系研究科","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"THE SOCIETY OF NUCLEAR MEDICINE INC"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0161-5505","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Noda, Akihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takamatsu, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Murakami, Yoshihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yajima, Kazuyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tatsumi, Mitsuyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichise, Rikiya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishimura, Shintaro"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-NODA-A-105.pdf","filesize":[{"value":"128.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-NODA-A-105.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/13102/files/ME-PR-NODA-A-105.pdf"},"version_id":"c1d435d5-a6ed-45b5-b540-cb3450aa6351"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"13102","relation_version_is_last":true,"title":["Measurement of brain concentration of FK960 for development of a novel antidementia drug : A PET study in conscious rhesus monkeys"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T09:48:01.141753+00:00"}